<DOC>
	<DOCNO>NCT02003872</DOCNO>
	<brief_summary>This open-label trial investigate effect Spatz 3 intragastric balloon weight loss obesity associate co- morbidity . The study aim evaluate effect intra gastric balloon weight reduction relate co- morbidity 1 year balloon implantation year follow explantation .</brief_summary>
	<brief_title>The Long Term Effect Adjustable Spaatz 3 Intragastric Balloon Weight Loss</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<criteria>1 . Subjects willing comply study requirement sign informed consent form . 2 . Age 1870 3 . BMI ≥ 35 kg/m² BMI ≥ 30 kg/m² hypertension diabetes mellitus 4 . Documented negative pregnancy test woman childbearing potential . 5 . Women childbearing potential agree remain contraceptive duration trial participation . 1 . Subjects receive prescription counter weight loss medication within 30 day prior randomization ( include GLP1 analog ) . 2 . Previous GI surgery could preclude ability place device . 3 . Subjects history abnormal GI anatomical finding document image study , opinion investigator , may impair implantation IGB device 4 . Subjects severe GERD respond Proton Pump Inhibitor ( PPI ) 5 . Known abnormal pathology condition upper gastrointestinal tract . 6 . Subjects symptomatic gallstone within 6 month prior randomization 7 . Coagulopathy define hgb &lt; 10g/dl platelet &lt; 100,000/ml diagnosis hemophilia , factor X deficiencies fibrinogen abnormality 8 . Subjects require prescription antithrombotic therapy ( i.e . anticoagulant antiplatelet agent ) 9 . Subjects unable discontinue NSAIDs ( nonsteroidal antiinflammatory drug ) drug bleed potential side effect study duration . 10 . Subject enrol another investigational study within 3 month participation current study 11 . Subjects reside within 3 hour drive distance study center .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>